Europe Cancer Therapeutics Market
Historic Data:    |   Base Year: 2023   |   Forecast Period: 2024-2031
Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis

No. of Pages: 150    |    Report Code: BMIRE00031444    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
Europe Cancer Therapeutics Market
Free Sample Buy Now

1. Introduction

1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
  • 3.2.1 Hypothesis formulation:
  • 3.2.2 Macro-economic factor analysis:
  • 3.2.3 Developing base number:
  • 3.2.4 Data Triangulation:
  • 3.2.5 Country level data:

4. Europe Cancer Therapeutics Market Landscape

4.1 Market Overview
4.2 Porter's Five Forces Analysis
  • 4.2.1 Bargaining Power of Suppliers
  • 4.2.2 Bargaining Power of Buyers
  • 4.2.3 Threat of New Entrants
  • 4.2.4 Competitive Rivalry
  • 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
  • 4.3.1 Raw Material Suppliers
  • 4.3.2 Manufacturers
  • 4.3.3 Distributors/Suppliers
  • 4.3.4 End Users

5. Europe Cancer Therapeutics Market – Key Market Dynamics

5.1 Growth Drivers
  • 5.1.1 Rising Prevalence of Cancer
  • 5.1.2 Favorable Reimbursement Scenario for Novel Therapeutics
  • 5.1.3 Improvement in Diagnosis Rate of Cancer
5.2 Market Opportunities
  • 5.2.1 Government Intervention across Developing Nations to Improve the Access of Life-saving Drugs
  • 5.2.2 Rising Investments in the Development of Advanced Drug Development Platforms
  • 5.2.3 Growing Number of Clinical trials for Anticancer Drugs
5.3 Future Trends
  • 5.3.1 Emergence of Advanced Cell & Gene Therapies
  • 5.3.2 Rising Adoption of Precision Medicine and Personalized Therapeutics
  • 5.3.3 Improvement in Diagnosis Rate of Cancer
5.4 Impact of Drivers and Restraints

6. Europe Cancer Therapeutics Market Regional Analysis

6.1 Europe Cancer Therapeutics Market Overview
6.2 Europe Cancer Therapeutics Market Revenue 2021-2031 (US$ Million)
6.3 Europe Cancer Therapeutics Market Forecast Analysis

7. Europe Cancer Therapeutics Market Analysis – by Therapy Type

7.1 Chemotherapy
  • 7.1.1 Overview
  • 7.1.2 Chemotherapy: Europe Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Targeted Therapy
  • 7.2.1 Overview
  • 7.2.2 Targeted Therapy: Europe Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Radiation Therapy
  • 7.3.1 Overview
  • 7.3.2 Radiation Therapy: Europe Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
7.4 Hormone Therapy
  • 7.4.1 Overview
  • 7.4.2 Hormone Therapy: Europe Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
7.5 Other Therapy Types
  • 7.5.1 Overview
  • 7.5.2 Other Therapy Types: Europe Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)

8. Europe Cancer Therapeutics Market Analysis – by Indications

8.1 Blood Cancer
  • 8.1.1 Overview
  • 8.1.2 Blood Cancer: Europe Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
8.2 Lung Cancer
  • 8.2.1 Overview
  • 8.2.2 Lung Cancer: Europe Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
8.3 Breast Cancer
  • 8.3.1 Overview
  • 8.3.2 Breast Cancer: Europe Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
8.4 Colorectal Cancer
  • 8.4.1 Overview
  • 8.4.2 Colorectal Cancer: Europe Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
8.5 Prostate Cancer
  • 8.5.1 Overview
  • 8.5.2 Prostate Cancer: Europe Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
8.6 Stomach Cancer
  • 8.6.1 Overview
  • 8.6.2 Stomach Cancer: Europe Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
8.7 Cervical Cancer
  • 8.7.1 Overview
  • 8.7.2 Cervical Cancer: Europe Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
8.8 Liver & Intrahepatic Bile Duct Cancer
  • 8.8.1 Overview
  • 8.8.2 Liver & Intrahepatic Bile Duct Cancer: Europe Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
8.9 Thyroid Cancer
  • 8.9.1 Overview
  • 8.9.2 Thyroid Cancer: Europe Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
8.10 Other Indications
  • 8.10.1 Overview
  • 8.10.2 Other Indications: Europe Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)

9. Europe Cancer Therapeutics Market Analysis – by Distribution Channel

9.1 Hospital Pharmacies
  • 9.1.1 Overview
  • 9.1.2 Other Indications: Europe Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
9.2 Retail Pharmacies
  • 9.2.1 Overview
  • 9.2.2 Other Indications: Europe Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
9.3 Online Channel
  • 9.3.1 Overview
  • 9.3.2 Other Indications: Europe Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)

10. Europe Cancer Therapeutics Market – Europe Analysis

10.1 Europe
  • 10.1.1 Europe Cancer Therapeutics Market Breakdown, by Key Country, 2025 and 2031 (%)
  • 10.1.1.1 Europe Cancer Therapeutics Market – Revenue and Forecast Analysis – by Country
  • 10.1.1.1 UK: Europe Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
    • 10.1.1.1.1 UK: Europe Cancer Therapeutics Market Breakdown, by Therapy Type
    • 10.1.1.1.2 UK: Europe Cancer Therapeutics Market Breakdown, by Indications
    • 10.1.1.1.3 UK: Europe Cancer Therapeutics Market Breakdown, by Distribution Channel
  • 10.1.1.2 Germany: Europe Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
    • 10.1.1.2.1 Germany: Europe Cancer Therapeutics Market Breakdown, by Therapy Type
    • 10.1.1.2.2 Germany: Europe Cancer Therapeutics Market Breakdown, by Indications
    • 10.1.1.2.3 Germany: Europe Cancer Therapeutics Market Breakdown, by Distribution Channel
  • 10.1.1.3 France: Europe Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
    • 10.1.1.3.1 France: Europe Cancer Therapeutics Market Breakdown, by Therapy Type
    • 10.1.1.3.2 France: Europe Cancer Therapeutics Market Breakdown, by Indications
    • 10.1.1.3.3 France: Europe Cancer Therapeutics Market Breakdown, by Distribution Channel
  • 10.1.1.4 Russia: Europe Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
    • 10.1.1.4.1 Russia: Europe Cancer Therapeutics Market Breakdown, by Therapy Type
    • 10.1.1.4.2 Russia: Europe Cancer Therapeutics Market Breakdown, by Indications
    • 10.1.1.4.3 Russia: Europe Cancer Therapeutics Market Breakdown, by Distribution Channel
  • 10.1.1.5 Italy: Europe Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
    • 10.1.1.5.1 Italy: Europe Cancer Therapeutics Market Breakdown, by Therapy Type
    • 10.1.1.5.2 Italy: Europe Cancer Therapeutics Market Breakdown, by Indications
    • 10.1.1.5.3 Italy: Europe Cancer Therapeutics Market Breakdown, by Distribution Channel
  • 10.1.1.6 Rest of Europe: Europe Cancer Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
    • 10.1.1.6.1 Rest of Europe: Europe Cancer Therapeutics Market Breakdown, by Therapy Type
    • 10.1.1.6.2 Rest of Europe: Europe Cancer Therapeutics Market Breakdown, by Indications
    • 10.1.1.6.3 Rest of Europe: Europe Cancer Therapeutics Market Breakdown, by Distribution Channel

11. Competitive Landscape

11.1 Heat Map Analysis
11.2 Company Positioning and Concentration

12. Europe Cancer Therapeutics Market Industry Landscape

12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 Astellas Pharma Inc
  • 13.1.1 Key Facts
  • 13.1.2 Business Description
  • 13.1.3 Products and Services
  • 13.1.4 Financial Overview
  • 13.1.5 SWOT Analysis
  • 13.1.6 Key Developments
13.2 Eli Lilly and Co
  • 13.2.1 Key Facts
  • 13.2.2 Business Description
  • 13.2.3 Products and Services
  • 13.2.4 Financial Overview
  • 13.2.5 SWOT Analysis
  • 13.2.6 Key Developments
13.3 Novartis AG
  • 13.3.1 Key Facts
  • 13.3.2 Business Description
  • 13.3.3 Products and Services
  • 13.3.4 Financial Overview
  • 13.3.5 SWOT Analysis
  • 13.3.6 Key Developments
13.4 Merck KGaA
  • 13.4.1 Key Facts
  • 13.4.2 Business Description
  • 13.4.3 Products and Services
  • 13.4.4 Financial Overview
  • 13.4.5 SWOT Analysis
  • 13.4.6 Key Developments
13.5 AstraZeneca
  • 13.5.1 Key Facts
  • 13.5.2 Business Description
  • 13.5.3 Products and Services
  • 13.5.4 Financial Overview
  • 13.5.5 SWOT Analysis
  • 13.5.6 Key Developments
13.6 Pfizer Inc
  • 13.6.1 Key Facts
  • 13.6.2 Business Description
  • 13.6.3 Products and Services
  • 13.6.4 Financial Overview
  • 13.6.5 SWOT Analysis
  • 13.6.6 Key Developments
13.7 Hoffmann-La Roche Ltd
  • 13.7.1 Key Facts
  • 13.7.2 Business Description
  • 13.7.3 Products and Services
  • 13.7.4 Financial Overview
  • 13.7.5 SWOT Analysis
  • 13.7.6 Key Developments
13.8 Johnson & Johnson
  • 13.8.1 Key Facts
  • 13.8.2 Business Description
  • 13.8.3 Products and Services
  • 13.8.4 Financial Overview
  • 13.8.5 SWOT Analysis
  • 13.8.6 Key Developments
13.9 AbbVie Inc
  • 13.9.1 Key Facts
  • 13.9.2 Business Description
  • 13.9.3 Products and Services
  • 13.9.4 Financial Overview
  • 13.9.5 SWOT Analysis
  • 13.9.6 Key Developments
13.10 Bristol-Myers Squibb Co
  • 13.10.1 Key Facts
  • 13.10.2 Business Description
  • 13.10.3 Products and Services
  • 13.10.4 Financial Overview
  • 13.10.5 SWOT Analysis
  • 13.10.6 Key Developments

14. Appendix

14.1 About Business Market Insights

The List of Companies - E Market

europe-cancer-therapeutics-market